Catapult Ventures Group

Portfolio responsibility is assigned to the executive team member who can add the most value to a given company, based on sector and stage expertise. That person serves as an active board member, involved in strategy, senior hiring, customer introductions, and financial structuring. The firm describes this as a relationship-driven model rather than a pooled investment committee approach.

The firm covers the full spectrum from seed and start-up to growth capital, expansion, management buy-ins, and management buyouts. It also participates in co-investment and general venture. This staging is supported by a track record of pre-revenue IP development all the way through to company floatation.

A team of eight named executives leads investment decisions, including Duncan Cameron, Professor Rob Carroll, Dr Tony Flinn, and Kevin D'Silva. The firm emphasizes that each executive has direct portfolio responsibility, rather than filtering decisions through a detached central committee.

Catapult operates discrete venture capital funds — historically totalling approximately £130m — into which public and private sector investors commit. Within those vehicles, the team makes direct equity investments and co-investments, and actively manages portfolio companies through board seats.

Since 2015, the firm reports 15 profitable exits averaging 4.6x money multiple. Disclosed realisations include R2C Online (12.6x), Accutronics (9.1x), Yospace (6.9x), Oxford Cryosystems (5.2x), Systems Integration (4.9x), and Lumora (4.7x). Additional exits are listed on the firm's 'Selected Realised' page.

The firm does not publish an explicit exclusions list. Its disclosed focus areas include healthcare, pharmaceuticals, diagnostics, biotechnology, medical devices, consumer, industrial and environmental technologies, and software. Sectors outside these areas may not receive active coverage.

Catapult relies on the deep sector networks of its long-tenured executive team, many of whom have decades of UK venture experience. The active board model — where partners embed in portfolio companies — also generates downstream co-investment referrals and management relationships across healthcare, industrial tech, and software.